<DOC>
	<DOCNO>NCT01293630</DOCNO>
	<brief_summary>The primary objective study determine maximum tolerate dose ( MTD ) base incidence dose limit toxicity ( DLT ) maximum administer dose ( MAD ) ombrabulin combine paclitaxel carboplatin administer every 3 week patient advance solid tumor . Secondary Objectives : - To assess overall safety profile combination therapy - To characterize pharmacokinetic profile ombrabulin , active metabolite RPR 258063 , paclitaxel , carboplatin use combination - To document objective tumor response</brief_summary>
	<brief_title>A Dose-escalation Study Ombrabulin Combination With Paclitaxel Carboplatin Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The duration study patient include 4-week screening phase , 21-day study treatment cycle , end treatment visit follow-up period .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : Patients advance solid tumor combination paclitaxel carboplatin potentially effective lung cancer , epithelial ovarian cancer . Patients sign dated Institutional Review Board ( IRB ) approve patient informed consent form prior study enrollment performance studyspecific procedure . Exclusion criterion : Less 20 75 year age ECOG performance status ≥2 . Patients 1 line previous chemotherapy advance metastatic disease ( adjuvant/neoadjuvant target agent [ eg gefitinib ] exclude ) Concurrent treatment anticancer therapy ( except palliative radiotherapy ) , Women childbearing potential agree contraception . Washout period le 28 day prior anticancer therapy Symptomatic brain metastasis carcinomatous leptomeningitis . Other serious illness medical condition Current peripheral neuropathy ≥grade 2 ototoxicity , Absolute neutrophils count &lt; 1.5 x 10E9/L . − Platelets count &lt; 100 x 10E9/L . − hemoglobin &lt; 9.0 g/dL ( without red blood cell transfusion within 28 day test ) . − Creatinine Clearance &lt; 55 mL/min . − Total bilirubin &gt; upper normal limit institutional norm . − ALT/AST &gt; 1.5 time upper normal limit institutional norm . − AP &gt; 2.5 time upper normal limit institutional norm . Medical history myocardial infarction , angina pectoris , congestive heart failure , coronary artery bypass graft , arrhythmia , stroke history arterial venous thromboembolism within past 180 day require anticoagulant . Patient LVEF &lt; 50 % echocardiography . Patient uncontrolled hypertension patient organ damage relate hypertension leave ventricular hypertrophy grade 2 ocular fundoscopic change kidney impairment . Hypertension define systolic BP &gt; 140 mmHg diastolic BP &gt; 90 mmHg two repeat measurement 30 minute interval . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>